Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis

NCT02532764 is registered in ClinicalTrials.gov with ProQR Therapeutics as lead sponsor.

NCT NCT02532764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02532764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Lead sponsor
ProQR Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2015
Completion date
September 14, 2017
Enrollment
70 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis